Advertisement

A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF)

  • Rajeev Masson
  • Andrew P. AmbrosyEmail author
  • Kevin Kheder
  • Marat Fudim
  • Robert M. Clare
  • Adrian Coles
  • Adrian F. Hernandez
  • Randall C. Starling
  • Justin A. Ezekowitz
  • Christopher M. O’Connor
  • Robert J. Mentz
Original Article
  • 15 Downloads
Part of the following topical collections:
  1. Special Issue: Volume Management in Heart Failure
  2. Special Issue: Volume Management in Heart Failure

Abstract

Patients hospitalized for heart failure (HF) remain at high risk for early readmission. A post hoc analysis was performed of the biomarker substudy of the ASCEND-HF trial. An in-hospital congestion score was derived using orthopnea, pedal edema, and NT-proBNP levels. Its added prognostic value beyond traditional risk factors was assessed by determining the net reclassification index (NRI). Study participants (n = 884) had a median age (years) of 67 (55–77), 68% were male, and the median (25th–75th) ejection fraction (%) was 26 (20–40). After adjustment, increasing congestion score was associated with 30-day all-cause mortality or HF hospitalization (odds ratio = 1.51, 95% confidence interval [CI] 1.28–1.77, p < 0.001) and 180-day all-cause mortality (hazard ratio = 1.48, 95% CI 1.28–1.72, p < 0.001). However, adding the congestion score to the multivariable model did not significantly impact the NRI. A higher in-hospital congestion score portended a poor short-term prognosis but did not significantly reclassify risk.

Keywords

Congestion Natriuretic peptides Heart failure Readmission Mortality 

Abbreviations

HF

Heart failure

NT-proBNP

Amino-terminal pro-B-type natriuretic peptide

CV

Cardiovascular

JVP

Jugular venous pulsation

SBP

Systolic blood pressure

BUN

Blood urea nitrogen

NRI

Net reclassification index

IDI

Integrated discrimination improvement

CCS

Clinical congestion score

OR

Odds ratio

CI

Confidence interval

HR

Hazard ratio

CIED

Cardiac implantable electronic device

Notes

Funding Information

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Scios Inc. (Mountain View, CA, USA) provided financial and material support for the ASCEND-HF trial. Database management and statistical analysis was performed by the Duke Clinical Research Institute.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that there are no conflicts of interest.

Informed Consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.

Disclaimer

The authors take responsibility for the manuscript’s integrity, and had complete control and authority over its preparation and the decision to publish.

References

  1. 1.
    Ambrosy, A. P., Fonarow, G. C., Butler, J., et al. (2014). The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. Journal of the American College of Cardiology, 63, 1123–1133.CrossRefGoogle Scholar
  2. 2.
    Gheorghiade, M., Abraham, W. T., Albert, N. M., et al. (2006). Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA, 296, 2217–2226.CrossRefGoogle Scholar
  3. 3.
    O'Connor, C. M., Abraham, W. T., Albert, N. M., et al. (2008). Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). American Heart Journal, 156, 662–673.CrossRefGoogle Scholar
  4. 4.
    Abraham, W. T., Fonarow, G. C., Albert, N. M., et al. (2008). Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Journal of the American College of Cardiology, 52, 347–356.CrossRefGoogle Scholar
  5. 5.
    Fudim, M., Parikh, K. S., Dunning, A., et al. (2018). Relation of volume overload to clinical outcomes in acute heart failure (from ASCEND-HF). The American Journal of Cardiology, 122, 1506–1512.CrossRefGoogle Scholar
  6. 6.
    O’Connor, C. M., Miller, A. B., Blair, J. E. A., et al. (2010). Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program. American Heart Journal, 159, 841–849 e1.CrossRefGoogle Scholar
  7. 7.
    Ambrosy, A. P., Pang, P. S., Khan, S., et al. (2013). Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. European Heart Journal, 34, 835–843.CrossRefGoogle Scholar
  8. 8.
    Mentz, R. J., Mi, X., Sharma, P. P., et al. (2015). Relation of dyspnea severity on admission for acute heart failure with outcomes and costs. The American Journal of Cardiology, 115, 75–81.CrossRefGoogle Scholar
  9. 9.
    Yancy Clyde, W., Jessup, M., Bozkurt, B., et al. (2013). 2013 ACCF/AHA guideline for the management of heart failure. Circulation, 128, e240–e327.PubMedGoogle Scholar
  10. 10.
    Gheorghiade, M., Follath, F., Ponikowski, P., et al. (2010). Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure, 12, 423–433.CrossRefGoogle Scholar
  11. 11.
    Yancy Clyde, W., Jessup, M., Bozkurt, B., et al. (2017). 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 136, e137–ee61.PubMedGoogle Scholar
  12. 12.
    Hernandez, A. F., O'Connor, C. M., Starling, R. C., et al. (2009). Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). American Heart Journal, 157, 271–277.CrossRefGoogle Scholar
  13. 13.
    O'Connor, C. M., Starling, R. C., Hernandez, A. F., et al. (2011). Effect of nesiritide in patients with acute decompensated heart failure. New England Journal of Medicine, 365, 32–43.CrossRefGoogle Scholar
  14. 14.
    Khazanie, P., Heizer, G. M., Hasselblad, V., et al. (2015). Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. American Heart Journal, 170, 290 7.e1.CrossRefGoogle Scholar
  15. 15.
    Jourdain, P., Jondeau, G., Funck, F., et al. (2007). Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. Journal of the American College of Cardiology, 49, 1733–1739.CrossRefGoogle Scholar
  16. 16.
    Porapakkham, P., Porapakkham, P., Zimmet, H., Billah, B., & Krum, H. (2010). B-type natriuretic peptide–guided heart failure therapy: a meta-analysis. Archives of Internal Medicine, 170, 507–514.CrossRefGoogle Scholar
  17. 17.
    Felker, G. M., Ahmad, T., Anstrom, K. J., et al. (2014). Rationale and design of the GUIDE-IT study: guiding evidence based therapy using biomarker intensified treatment in heart failure. JACC: Heart Failure, 2, 457–465.PubMedGoogle Scholar
  18. 18.
    Kleiner Shochat, M., Fudim, M., Shotan, A., et al. (2018). Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE-HF extended trial. ESC Heart Fail, 5, 788–799.CrossRefGoogle Scholar
  19. 19.
    Fudim, M., & Miller, W. L. (2018). Calculated estimates of plasma volume in patients with chronic heart failure-comparison with measured volumes. Journal of Cardiac Failure, 24, 553–560.CrossRefGoogle Scholar
  20. 20.
    Cotter, G., Felker, G. M., Adams, K. F., Milo-Cotter, O., & O'Connor, C. M. (2008). The pathophysiology of acute heart failure--is it all about fluid accumulation? American Heart Journal, 155, 9–18.CrossRefGoogle Scholar
  21. 21.
    Fudim, M., Hernandez, A. F., & Felker, G. M. (2017). Role of volume redistribution in the congestion of heart failure. Journal of the American Heart Association, 6, e006817.CrossRefGoogle Scholar
  22. 22.
    Mullens, W., Abrahams, Z., Francis, G. S., et al. (2008). Sodium nitroprusside for advanced low-output heart failure. Journal of the American College of Cardiology, 52, 200–207.CrossRefGoogle Scholar
  23. 23.
    Cerbin, L. P., Ambrosy, A. P., Greene, S. J., et al. (2018). Is time of the essence? The impact of time of hospital presentation in acute heart failure: insights from ASCEND-HF trial. JACC Heart Fail, 6, 298–307.CrossRefGoogle Scholar
  24. 24.
    Perez, A. L., Grodin, J. L., Wu, Y., et al. (2016). Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. European Journal of Heart Failure, 18, 290–297.CrossRefGoogle Scholar
  25. 25.
    Small, R. S., Whellan, D. J., Boyle, A., et al. (2014). Implantable device diagnostics on day of discharge identify heart failure patients at increased risk for early readmission for heart failure. European Journal of Heart Failure, 16, 419–425.CrossRefGoogle Scholar
  26. 26.
    Felker, G. M., Duke Clinical Research Institute D, Carolina, N., Anstrom, K. J., et al. (2019). Effect of natriuretic peptide–guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA, 318, 713–720.CrossRefGoogle Scholar
  27. 27.
    Vidan, M. T., Blaya-Novakova, V., Sanchez, E., Ortiz, J., Serra-Rexach, J. A., & Bueno, H. (2016). Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure. European Journal of Heart Failure, 18, 869–875.CrossRefGoogle Scholar
  28. 28.
    Gheorghiade, M., Konstam, M. A., Burnett, J. C., et al. (2007). Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA, 297, 1332–1343.CrossRefGoogle Scholar
  29. 29.
    Teerlink, J. R., Cotter, G., Davison, B. A., et al. (2013). Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. The Lancet, 381, 29–39.CrossRefGoogle Scholar
  30. 30.
    Chioncel, O., Collins, S. P., Greene, S. J., et al. (2016). Natriuretic peptide-guided management in heart failure. Journal of Cardiovascular Medicine (Hagerstown, Md.), 17, 556–568.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Rajeev Masson
    • 1
  • Andrew P. Ambrosy
    • 1
    • 2
    Email author
  • Kevin Kheder
    • 1
  • Marat Fudim
    • 3
    • 4
  • Robert M. Clare
    • 4
  • Adrian Coles
    • 4
  • Adrian F. Hernandez
    • 3
    • 4
  • Randall C. Starling
    • 5
  • Justin A. Ezekowitz
    • 6
  • Christopher M. O’Connor
    • 7
  • Robert J. Mentz
    • 3
    • 4
  1. 1.Kaiser Permanente San Francisco Medical CenterSan FranciscoUSA
  2. 2.Division of ResearchKaiser Permanente Northern CaliforniaOaklandUSA
  3. 3.Duke University Medical CenterDurhamUSA
  4. 4.Duke Clinical Research InstituteDurhamUSA
  5. 5.Cleveland Clinic FoundationClevelandUSA
  6. 6.The Canadian VIGOUR CentreUniversity of AlbertaEdmontonCanada
  7. 7.INOVA Heart and Vascular InstituteFalls ChurchUSA

Personalised recommendations